KOD (Kodiak Sciences) Growth Rank : 0 (As of Dec. 15, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences Growth Rank?

Kodiak Sciences has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Kodiak Sciences Growth Rank Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

KOD:Mexico K27:Germany

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Executives

John A. Borgeson	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Jason Ehrlich	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth	director, 10 percent owner, officer: Chairman, President and CEO	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang	officer: See Remarks	2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek	director	P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016